# Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers

> **NCT06918951** · NA · RECRUITING · sponsor: **British Columbia Cancer Agency** · enrollment: 194 (estimated)

## Conditions studied

- Oligoprogression
- Oligometastatic Disease
- OligoProgressive Metastatic Disease

## Interventions

- **RADIATION:** Stereotactic ablative radiotherapy (SABR)
- **RADIATION:** Palliative radiotherapy

## Key facts

- **NCT ID:** NCT06918951
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-04
- **Primary completion:** 2030-06-01
- **Final completion:** 2033-06-01
- **Target enrollment:** 194 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06918951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06918951, "Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06918951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*